Shigemi Matsumoto

Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda et al. · Journal of Clinical Oncology · 2015 · 1.2K citations

Medicine, Oncology, Pharmacology +17

The Baseline Ratio of Neutrophils to Lymphocytes Is Associated with Patient Prognosis in Advanced Gastric Cancer

Takeharu Yamanaka, Shigemi Matsumoto, Satoshi Teramukai et al. · Oncology · 2007 · 464 citations

Medicine, Hematology, Oncology +16

A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer

Masashi Kanai, Kenichi Yoshimura, Masanori Asada et al. · Cancer Chemotherapy and Pharmacology · 2010 · 398 citations · Full text

Medicine, Oncology, Pharmacology +10

Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors

Motoo Nomura, Ryosuke Nagatomo, Keitaro Doi et al. · JAMA Network Open · 2020 · 378 citations · Full text

Life Sciences, Immunology, Oncology +17

Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers

Masashi Kanai, Atsushi Imaizumi, Yoshihiko Otsuka et al. · Cancer Chemotherapy and Pharmacology · 2011 · 253 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17